Blue Note Therapeutics receives breakthrough device designation for prescription only digital therapeutic for acute myeloid leukaemia

Blue Note Therapeutics

31 January 2022 - Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced that the U.S. FDA has granted breakthrough device designation for BNT200. 

BNT200 is a first of its kind prescription-only digital therapeutic to treat anxiety and depressive symptoms in adults with acute myeloid leukaemia who are hospitalised for a regimen of high-intensity induction chemotherapy.

Read Blue Note Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder